Haemonetics FY2027 EPS Forecast Lowered by Zacks Research

Haemonetics Co. (NYSE:HAE - Free Report) - Equities research analysts at Zacks Research decreased their FY2027 earnings per share estimates for shares of Haemonetics in a note issued to investors on Monday, February 3rd. Zacks Research analyst R. Department now expects that the medical instruments supplier will earn $5.90 per share for the year, down from their prior estimate of $5.91. The consensus estimate for Haemonetics' current full-year earnings is $4.59 per share.

Several other research analysts also recently weighed in on the stock. Raymond James reissued a "strong-buy" rating and issued a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a research note on Friday. Barrington Research cut their price objective on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research report on Friday. Needham & Company LLC lowered their target price on shares of Haemonetics from $112.00 to $108.00 and set a "buy" rating for the company in a research note on Friday. JMP Securities reduced their price target on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research note on Friday. Finally, JPMorgan Chase & Co. started coverage on Haemonetics in a report on Friday, December 6th. They set an "overweight" rating and a $116.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $101.67.

Haemonetics Price Performance

Shares of HAE stock traded down $3.66 during trading hours on Wednesday, hitting $59.34. The company's stock had a trading volume of 2,702,592 shares, compared to its average volume of 959,630. The company has a current ratio of 3.97, a quick ratio of 2.09 and a debt-to-equity ratio of 1.35. Haemonetics has a twelve month low of $59.09 and a twelve month high of $97.97. The stock has a market cap of $2.98 billion, a price-to-earnings ratio of 23.36, a P/E/G ratio of 0.98 and a beta of 0.39. The business has a fifty day moving average of $76.38 and a 200-day moving average of $78.41.

Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Nisa Investment Advisors LLC increased its position in shares of Haemonetics by 124.2% in the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier's stock worth $92,000 after acquiring an additional 632 shares in the last quarter. Parkside Financial Bank & Trust increased its holdings in Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after purchasing an additional 240 shares in the last quarter. AlphaQuest LLC lifted its stake in shares of Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after purchasing an additional 1,826 shares in the last quarter. KBC Group NV boosted its position in shares of Haemonetics by 54.6% in the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after buying an additional 712 shares during the period. Finally, iSAM Funds UK Ltd acquired a new stake in shares of Haemonetics in the third quarter valued at about $204,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.